eISSN: 2449-8580
ISSN: 1734-3402
Family Medicine & Primary Care Review
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search

Open access

without publication fees
4/2022
vol. 24
 
Share:
Send email
Share:
Review paper

The impact of socioeconomic status on prostate cancer screening and access to medical care

Seyed Saeed Tamehri Zadeh
1
,
Amirreza Nabighadim
2
,
Ali Mohammad Fakhr Yasseri
1
,
Seyed Mohammad Kazem Aghamir
1

  1. Urology Research Centre, Tehran University of Medical Sciences, Tehran, Iran
  2. Paediatric Urology and Regenerative Medicine Research Centre, Children’s Medical Centre, Tehran University of Medical Sciences, Tehran, Iran
Family Medicine & Primary Care Review 2022; 24(4): 375–378
DOI: https://doi.org/10.5114/fmpcr.2022.120863
Online publish date: 2022/12/21
Article file
- 14 FM&PCR 4 22 - R - Tamehri Zadeh - The impact - 1204.pdf  [0.41 MB]
Get citation
 
PlumX metrics:
 
1. Coffey DS. Prostate cancer. An overview of an increasing dilemma. Cancer 1993; 71(S3): 880–886.
2. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000; 14(19): 2410–2434.
3. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60(2): 70–98.
4. Steenland K, Rodriguez C, Mondul A, et al. Prostate cancer incidence and survival in relation to education (United States). Cancer Causes Control 2004; 15(9): 939–945.
5. Coughlin SS. A review of social determinants of prostate cancer risk, stage, and survival. Prostate Int 2020; 8(2): 49–54.
6. Tingen MS, Weinrich SP, Heydt DD, et al. Perceived benefits: a predictor of participation in prostate cancer screening. Cancer Nurs 1998; 21(5): 349–357.
7. Eeden S, Van Den, Enger S, Caan B, et al., eds. Predictors of having a prostate-specific antigen (PSA) test. Am J Epidemiol 2003; 157(11): S92–S92.
8. Ndubuisi SC, Kofie VY, Andoh JY, et al. Black-white differences in the stage at presentation of prostate cancer in the District of Columbia. Urology 1995; 46(1): 71–77.
9. Mihor A, Tomsic S, Zagar T, et al. Socioeconomic inequalities in cancer incidence in Europe: a comprehensive review of population-based epidemiological studies. Radiol Oncol 2020; 54(1): 1–13.
10. Badal S, Aiken W, Morrison B, et al. Disparities in prostate cancer incidence and mortality rates: solvable or not? Prostate 2020; 80(1): 3–16.
11. Mirzaei A, Akbari MR, Zadeh SST, et al. Novel combination therapy of prostate cancer cells with arsenic trioxide and flutamide: an in-vitro study. Tissue Cell 2022; 74: 101684, doi: 10.1016/j.tice.2021.101684.
12. Siegel RL, Miller K, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1): 5–29.
13. Liu L, Cozen W, Bernstein L, et al. Changing relationship between socioeconomic status and prostate cancer incidence. J Natl Cancer Inst 2001; 93(9): 705–709.
14. Lin K, Lipsitz R, Miller T, et al. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the US Preventive Services Task Force. Ann Intern Med 2008; 149(3): 192–199.
15. Moyer VA. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157(2): 120–134.
16. Ilic D, Neuberger MM, Djulbegovic M, et al. Screening for prostate cancer. Cochrane Database Syst Rev 2013; 2013(1): CD004720, doi: 10.1002/14651858.CD004720.pub3.
17. Smith RA, Andrews KS, Brooks D, et al. Cancer screening in the United States, 2018: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2018; 68(4): 297–316, doi: 10.3322/caac.21446.
18. Bell N, Gorber SC, Shane A, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ 2014; 186(16): 1225–1234.
19. Carroll PR, Parsons JK, Andriole G, et al. NCCN guidelines insights: prostate cancer early detection, version 2.2016. J Natl Compr Canc Netw 2016; 14(5): 509–519.
20. Qaseem A, Barry MJ, Denberg TD, et al. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013; 158(10): 761–769.
21. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360(13): 1320–1328.
22. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. ARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 96. Alcohol Consumption and Ethyl Carbamate. Lyon: IARC; 1988.
23. Møller H, Tønnesen H. Alcohol drinking, social class and cancer. IARC Sci Publ 1997; 138: 251–263.
24. Stellmen S, Resnicow K. Tobacco smoking, cancer and social class. IARC Sci Publ 1997; 138: 229–250.
25. Harvei S, Kravdal Ø. The importance of marital and socioeconomic status in incidence and survival of prostate cancer. Prev Med 1997; 26(5): 623–632.
26. Dorn HF, Cutler SJ. Morbidity from cancer in the United States. Public Health Monogr 1959; 56: 1–207.
27. Clemmesen J, Nielsen A. The social distribution of cancer in Copenhagen, 1943 to 1947. Br J Cancer 1951; 5(2): 159–171.
28. Cheng I, Witte JS, McClure LA, et al. Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California. Cancer Causes Control 2009; 20(8): 1431–1440.
29. Hastert TA, Beresford SA, Sheppard L, et al. Disparities in cancer incidence and mortality by area-level socioeconomic status: a multilevel analysis. J Epidemiol Community Health 2015; 69(2): 168–176.
30. Tomic K, Ventimiglia E, Robinson D, et al. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer 2018; 142(12): 2478–2484.
31. Morton Jr RA. Racial differences in adenocarcinoma of the prostate in North American men. Urology 1994; 44(5): 637–645.
32. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Int Med 1993; 118(10): 793–803.
33. Howard G, Anderson RT, Russell G, et al. Race, socioeconomic status, and cause-specific mortality. Ann Intern Med 1993; 118(10): 793–803.
34. Freeman VL, Ricardo AC, Campbell RT, et al. Association of Census Tract-Level Socioeconomic Status with Disparities in Prostate Cancer – Specific Survival Census Tract-Level SES and Prostate Cancer Survival. Cancer Epidemiol Biomarkers Prev 2011; 20(10): 2150–2159.
35. Kilpeläinen TP, Talala K, Raitanen J, et al. Prostate cancer and socioeconomic status in the Finnish randomized study of screening for prostate cancer. Am J Epidemiol 2016; 184(10): 720–731.
36. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 2002; 94(5): 334–357.
37. McFall SL, Hamm RM, Volk RJ. Exploring beliefs about prostate cancer and early detection in men and women of three ethnic groups. Patient Educ Couns 2006; 61(1): 109–116.
38. Weinrich SP, Seger R, Miller BL, et al. Knowledge of the limitations associated with prostate cancer screening among low-income men. Cancer Nurs 2004; 27(6): 442–451.
39. Rapiti E, Fioretta G, Schaffar R, et al. Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis. Cancer 2009; 115(23): 5556–5565.
40. Rundle A, Neckerman KM, Sheehan D, et al. A prospective study of socioeconomic status, prostate cancer screening and incidence among men at high risk for prostate cancer. Cancer Causes Control 2013; 24(2): 297–303.
41. Sanderson M, Coker AL, Perez A, et al. A multilevel analysis of socioeconomic status and prostate cancer risk. Ann Epidemiol 2006; 16(12): 901–907.
42. Ross L, Kohler CL, Grimley DM, et al. Toward a model of prostate cancer information seeking: identifying salient behavioral and normative beliefs among African American men. Health Educ Behav 2007; 34(3): 422–440.
43. Winterich JA, Grzywacz JG, Quandt SA, et al. Men’s knowledge and beliefs about prostate cancer: education, race, and screening status. Ethn Dis 2009; 19(2): 199–203.
44. Oranusi C, Mbieri U, Oranusi I, et al. Prostate cancer awareness and screening among male public servants in Anambra State, Nigeria. Afr J Urol 2012; 18(2): 72–74.
45. Kangmennaang J, Mkandawire P, Luginaah I. What prevents men aged 40–64 years from prostate cancer screening in Namibia? J Cancer Epidemiol 2016; 2016: 7962502.
46. Fernandez-Quilez A, Germán Borda M, Carreño GL, et al. Prostate cancer screening and socioeconomic disparities in mexican older adults. Salud Publica Mex 2020; 62(2): 121–122.
Copyright: © 2022 Family Medicine & Primary Care Review. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.